sofosbuvir + GS-0938

**sofosbuvir + GS-0938** is a combination of two nucleotide analogue inhibitors of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. **Sofosbuvir** is a pyrimidine nucleotide analogue, and **GS-0938** is a purine nucleotide analogue. Both act as direct-acting antivirals (DAAs) and work by blocking viral replication. The combination was developed for oral, interferon-free therapy in chronic HCV infection and has shown substantial reductions in viral load and high effectiveness for reducing HCV RNA levels in phase 2 trials in treatment-naïve HCV genotype 1 patients; both agents demonstrated additive antiviral effects. No viral breakthroughs or resistance were observed in short-term studies[1][3][2]. Developed primarily by Gilead Sciences for HCV infection, this investigational combination was well tolerated in clinical trials, with no serious adverse events reported[1][2][3]. As both are nucleotide analogues targeting the same viral polymerase, further development focused on combining sofosbuvir with other classes of antivirals for greater efficacy.

Brand names

Sovaldi (for sofosbuvir)

Other names

sofosbuvir + PSI-352938sofosbuvir + PSI-7977